Shanghai Medicilon Inc
SSE:688202
Income Statement
Earnings Waterfall
Shanghai Medicilon Inc
Revenue
|
1.6B
CNY
|
Cost of Revenue
|
-1.1B
CNY
|
Gross Profit
|
500.7m
CNY
|
Operating Expenses
|
-324.3m
CNY
|
Operating Income
|
176.3m
CNY
|
Other Expenses
|
-1.3m
CNY
|
Net Income
|
175m
CNY
|
Income Statement
Shanghai Medicilon Inc
Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||
Revenue |
407
N/A
|
449
+10%
|
467
+4%
|
512
+9%
|
569
+11%
|
666
+17%
|
775
+16%
|
891
+15%
|
1 019
+14%
|
1 167
+15%
|
1 309
+12%
|
1 425
+9%
|
1 621
+14%
|
1 659
+2%
|
1 754
+6%
|
1 788
+2%
|
1 602
-10%
|
|
Gross Profit | ||||||||||||||||||
Cost of Revenue |
(259)
|
(288)
|
(300)
|
(324)
|
(359)
|
(392)
|
(447)
|
(493)
|
(559)
|
(638)
|
(724)
|
(788)
|
(897)
|
(982)
|
(1 033)
|
(1 100)
|
(1 101)
|
|
Gross Profit |
148
N/A
|
161
+9%
|
167
+4%
|
188
+12%
|
210
+12%
|
274
+30%
|
328
+20%
|
397
+21%
|
460
+16%
|
529
+15%
|
585
+11%
|
637
+9%
|
724
+14%
|
677
-7%
|
721
+7%
|
689
-4%
|
501
-27%
|
|
Operating Income | ||||||||||||||||||
Operating Expenses |
(77)
|
(92)
|
(98)
|
(103)
|
(112)
|
(130)
|
(146)
|
(169)
|
(190)
|
(207)
|
(225)
|
(269)
|
(305)
|
(318)
|
(332)
|
(322)
|
(324)
|
|
Selling, General & Administrative |
(59)
|
(69)
|
(73)
|
(75)
|
(81)
|
(87)
|
(101)
|
(115)
|
(127)
|
(131)
|
(154)
|
(192)
|
(221)
|
(221)
|
(238)
|
(227)
|
(225)
|
|
Research & Development |
(24)
|
(26)
|
(32)
|
(36)
|
(40)
|
(44)
|
(54)
|
(62)
|
(73)
|
(71)
|
(86)
|
(95)
|
(109)
|
(115)
|
(128)
|
(133)
|
(132)
|
|
Depreciation & Amortization |
0
|
(3)
|
0
|
0
|
0
|
(6)
|
0
|
0
|
0
|
(17)
|
0
|
0
|
0
|
(8)
|
0
|
0
|
0
|
|
Other Operating Expenses |
6
|
7
|
7
|
8
|
8
|
7
|
9
|
8
|
9
|
13
|
15
|
18
|
24
|
25
|
34
|
38
|
33
|
|
Operating Income |
71
N/A
|
70
-2%
|
69
-1%
|
85
+22%
|
98
+15%
|
143
+46%
|
182
+27%
|
228
+26%
|
270
+18%
|
322
+19%
|
360
+12%
|
368
+2%
|
419
+14%
|
358
-14%
|
389
+8%
|
367
-6%
|
176
-52%
|
|
Pre-Tax Income | ||||||||||||||||||
Interest Income Expense |
4
|
5
|
12
|
15
|
12
|
9
|
4
|
(1)
|
1
|
2
|
(0)
|
11
|
15
|
12
|
8
|
2
|
(5)
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
Gain/Loss on Disposition of Assets |
0
|
(0)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
|
Total Other Income |
(0)
|
3
|
2
|
2
|
1
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(2)
|
(1)
|
(2)
|
(1)
|
(2)
|
(2)
|
(2)
|
|
Pre-Tax Income |
74
N/A
|
78
+4%
|
82
+6%
|
101
+23%
|
111
+9%
|
150
+35%
|
185
+23%
|
226
+22%
|
270
+19%
|
323
+20%
|
358
+11%
|
378
+6%
|
432
+14%
|
368
-15%
|
395
+7%
|
367
-7%
|
171
-53%
|
|
Net Income | ||||||||||||||||||
Tax Provision |
(9)
|
(9)
|
(10)
|
(12)
|
(12)
|
(16)
|
(19)
|
(25)
|
(30)
|
(38)
|
(43)
|
(46)
|
(53)
|
(30)
|
(32)
|
(25)
|
4
|
|
Income from Continuing Operations |
66
|
69
|
72
|
89
|
99
|
134
|
166
|
201
|
240
|
285
|
314
|
332
|
379
|
338
|
363
|
342
|
175
|
|
Income to Minority Interest |
(2)
|
(2)
|
(2)
|
(3)
|
(4)
|
(5)
|
(7)
|
(6)
|
(4)
|
(2)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Net Income (Common) |
64
N/A
|
67
+4%
|
70
+5%
|
86
+23%
|
95
+10%
|
129
+37%
|
159
+23%
|
196
+23%
|
236
+20%
|
282
+20%
|
314
+11%
|
332
+6%
|
379
+14%
|
338
-11%
|
363
+7%
|
342
-6%
|
175
-49%
|
|
EPS (Diluted) |
1.38
N/A
|
1.36
-1%
|
1.13
-17%
|
1.39
+23%
|
1.52
+9%
|
2.09
+38%
|
2.57
+23%
|
2.25
-12%
|
2.71
+20%
|
2.32
-14%
|
3.62
+56%
|
3.82
+6%
|
3.11
-19%
|
2.78
-11%
|
2.97
+7%
|
2.8
-6%
|
1.46
-48%
|